Costo per responder del metotrexato rispetto ad altre terapie in pazienti con psoriasi a placche da moderata a grave in Italia

OBJECTIVE: Conventional synthetic disease modifying antirheumatic drugs (csDMARDs) were recommended in 2019 as first line therapy from Italian Medicines Agency (AIFA) for the treatment of moderate to severe psoriasis. Updated local guidelines recommended methotrexate (MTX) as the drug of first choic...

Descripción completa

Detalles Bibliográficos
Autores principales: Pompilio, Giuseppe, Integlia, Davide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AboutScience 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9668062/
https://www.ncbi.nlm.nih.gov/pubmed/36628309
http://dx.doi.org/10.33393/grhta.2022.2474

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9668062/
https://www.ncbi.nlm.nih.gov/pubmed/36628309
http://dx.doi.org/10.33393/grhta.2022.2474

Ejemplares similares